Pradeep Sushma, Jain Anisha S, Dharmashekara Chandan, Prasad Shashanka K, Kollur Shiva Prasad, Syed Asad, Shivamallu Chandan
Department of Biotechnology and Bioinformatics, School of Life Sciences, JSS Academy of Higher Education and Research, Mysuru, Karnataka, India.
Department of Sciences, Amrita School of Arts and Sciences, Amrita Vishwa Vidyapeetham, Mysuru Campus, Mysuru, Karnataka, India.
J Alzheimers Dis Rep. 2020 Oct 24;4(1):417-429. doi: 10.3233/ADR-200228.
Alzheimer's disease (AD) was first described in 1907 and got its name after Alois Alzheimer, a German psychiatrist and neuropathologist. This disease starts slow, increasing gradually to worsen in the due course of time. AD is mainly characterized by the associated dementia, which is a decline of cognitive effects such as memory, praxis, and orientation. The dementia is further highlighted by the presence of psychological and behavioral symptoms. Additionally, AD is also associated with the multiple interconnected pathways linked neuropathological changes such as the formation of neurofibrillary tangles and amyloid-β plaques inside the brain. AD therapeutics have been of prime concern over the decades, resulting in the elucidation of promising therapeutic targets. The requirement of AD stage dependent optimized conditions has necessitated a combinatorial approach toward treatment. The priority in AD research has remained to develop disease-modifying and development-reducing drugs for treatment regimens followed during the early and later stages, respectively.
阿尔茨海默病(AD)于1907年首次被描述,并以德国精神病学家和神经病理学家阿洛伊斯·阿尔茨海默的名字命名。这种疾病起病缓慢,随着时间的推移逐渐加重。AD的主要特征是相关的痴呆症,即记忆、实践和定向等认知功能的衰退。心理和行为症状的出现进一步凸显了痴呆症。此外,AD还与多种相互关联的神经病理变化途径有关,如大脑内神经原纤维缠结和β-淀粉样蛋白斑块的形成。几十年来,AD治疗一直是首要关注的问题,这导致了有前景的治疗靶点的阐明。AD阶段依赖性优化条件的要求使得治疗需要采用组合方法。AD研究的重点仍然是分别开发用于早期和晚期治疗方案的疾病修饰和疾病进展减缓药物。